Furthermore, Chiappinelli et al. also reported that DNMTi directly trigger the type I interferon response, which sensitizes melanoma to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) immunotherapy [43]. The gene discussed is CTLA4; the disease is melanoma.